Early Intensification will be given prior to Consolidation to patients with provisional standard-risk or high-risk ALL/LLy or any provisional low-risk patients with Day 15 MRD ≥1% as well as provisional low-risk LLy patients who do not obtain complete response at the end of Induction. For patients with Ph-like ALL that is targetable with JAK inhibitor and Day 15 MRD level ≥5% or end of Remission Induction ≥1% as well as all patients with early T cell precursor (ETP) ALL, ruxolitinib will be used. This includes, but is not limited to CRLF2, JAK2, and EPOR rearrangements and sequence/structural changes in JAK1/2/3, TYK2, IL7R, and SH2B3. Ruxolitinib will be added in LLy patients with activation of JAK-STAT signaling whose responses do not qualify complete response at the end of Remission Induction. Activation of JAK-STAT signaling is defined in ALL/LLy that contains genetic alterations associated with JAK-STAT pathway. Dasatinib will continue for patients with ABL1-class fusions. Bortezomib will be added for patients with no targetable lesions and Day 15 MRD >5% or Day 42 MRD >1% and LLy patients without targetable lesions whose responses do not qualify complete response at the end of Remission Induction.